Successful use of anti-CD19 CAR T cells in severe treatment-refractory stiff-person syndrome
Proceedings of the National Academy of Sciences · 25.06.2024 · 121 (26)
DOI: 10.1073/pnas.2403227121 ↗Kurz gefasst
Fallbericht in der Zeitschrift Proceedings of the National Academy of Sciences, online erschienen am 17.06.2024. Verfasst von Simon Faissner und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Ruhr-University Bochum, St. Josef-Hospital, Bochum 44791, Germany. Hauptthemen laut MEDLINE: Stiff-Person Syndrome, Immunotherapy, Adoptive, Antigens, CD19. Die Arbeit wurde bisher 84-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Rose Foundation, Nasch family.
Abstract (Originalsprache)
Treatment with autologous chimeric antigen receptor (CAR) T cells has emerged as a highly effective approach in neuroimmunological disorders such as myasthenia gravis. We report a case of successful anti-CD19 CAR T cell use in treatment-refractory stiff-person syndrome (SPS). To investigate clinical and immunological effects of anti-CD19 CAR T cell use in treatment-refractory SPS, a 69-y-old female with a 9-y history of treatment-refractory SPS with deteriorating episodes of stiffness received an infusion of autologous anti-CD19 CAR T cells (KYV-101) and was monitored clinically and immunologically for more than 6 mo. CAR T cell infusion resulted in reduced leg stiffness, drastic improvement in gait, walking speed increase over 100%, and daily walking distance improvement from less than 50 m to over 6 km within 3 mo. GABAergic medication (benzodiazepines) was reduced by 40%. KYV-101 CAR T cells were well tolerated with only low-grade cytokine release syndrome. This report of successful use of anti-CD19 CAR T cells in treatment-refractory SPS supports continued exploration of this approach in SPS and other B cell–related autoimmune disorders.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Ruhr-University Bochum, St. Josef-Hospital, Bochum 44791, Germany.
- Department of Neurology, Jena University Hospital, Jena 07747, Germany.
- Department of Neurology, Medical Faculty, Otto-von-Guericke University, Magdeburg 39120, Germany.
- Department of Hematology, Medical Faculty, Otto-von-Guericke University, Magdeburg 39120, Germany.
- Kyverna Therapeutics, Emeryville, CA 94608.
- Department of Haematology and Oncology, Ruhr-University Bochum, Knappschaftskrankenhaus Bochum, Bochum 44892, Germany.
ORCID-Profile: Simon Faissner, Jeremias Motte, Christian Geis, Aiden Haghikia, Dominic Borie, Roland Schroers, Ralf Gold
Förderung
- Rose Foundation
- Nasch family
Zitieren
APA
Faissner, S., Motte, J., Sgodzai, M., Geis, C., Haghikia, A., Mougiakakos, D., Borie, D., Schroers, R., & Gold, R. (2024). Successful use of anti-CD19 CAR T cells in severe treatment-refractory stiff-person syndrome. Proceedings of the National Academy of Sciences, 121(26). https://doi.org/10.1073/pnas.2403227121
Vancouver
Faissner S, Motte J, Sgodzai M, Geis C, Haghikia A, Mougiakakos D, et al. Successful use of anti-CD19 CAR T cells in severe treatment-refractory stiff-person syndrome. Proceedings of the National Academy of Sciences. 2024;121(26). doi:10.1073/pnas.2403227121
BibTeX
@article{Faissner2024,
author = {Faissner, Simon and Motte, Jeremias and Sgodzai, Melissa and Geis, Christian and Haghikia, Aiden and Mougiakakos, Dimitrios and Borie, Dominic and Schroers, Roland and Gold, Ralf},
title = {Successful use of anti-CD19 CAR T cells in severe treatment-refractory stiff-person syndrome},
journal = {Proceedings of the National Academy of Sciences},
year = {2024},
volume = {121},
number = {26},
doi = {10.1073/pnas.2403227121}
}
EUVIMED